Michael Quirmbach Email

Group CEO & President . CordenPharma

Current Roles

Employees:
1713
Revenue:
$344.3M
About
CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products and associated Packaging Services. Through a network of cGMP facilities across Europe and the US organized under four technology platforms – Peptides, Lipids & Carbohydrates – Injectables - Highly Potent & Oncology - Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value products. \n\n<< Peptides, Lipids & Carbohydrates >>\n\n• Synthetic Peptide API Production\n - Solid-phase, Liquid-phase, Hybrid Synthesis\n - cGMP & non-cGMP\n• Synthetic Lipids \n• Carbohydrates \n\n<< Sterile Injectables >>\n\n• New Development & Commercial Suites for Aseptic Filling with > 60.000 units \n per day (Pre-filled Syringes, Liquid or Lyophilized Vials)\n• Packaging, Labeling & Logistics\n• Sterile Emulsion Technology\n• Large Pre-Filled Syringes\n• Clinical Trial Services\n\n<< Highly Potent & Oncology >>\n\n• API Development & Commercial Manufacturing \n (SafeBridge Category 4, OEL ≤1 ng/m3)\n - New Development & Scale-up Capacity for Phase I/II Supply\n• Drug Product Development & Manufacturing\n - New Development Suite (CTD2) for Mid-scale Oral Dosage (up to 20 kg)\n - Sterile Liquid & Lyophilization\n - Primary & Secondary Packaging \n\n<< Small Molecules >>\n\n• Development & Commercial Manufacturing\n - Intermediates \n - APIs & Excipients\n - Clinical Supply Phases I-III\n• Proprietary & Generic Advanced Intermediates & APIs \n\nVisit > www.cordenpharma.com
CordenPharma Address
2075 55th St
Boulder, CO
United States
CordenPharma Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.